CMS switches to C2C Innovative Solutions for Medicare Advantage appeals
By HME News Staff
Updated 8:05 AM CDT, Mon April 6, 2026
WASHINGTON – The Centers for Medicare & Medicaid Services (CMS) has awarded the Part C Independent Review Entity (IRE) contract to C2C Innovative Solutions. Effective May 1, 2026, C2C will be responsible for conducting appeals of adverse reconsiderations issued by Part C plans, as well as reviews of plan dismissals of appellant reconsideration requests. The existing Part C IRE, Maximus, will continue to process appeal requests received on or before April 30, 2026. Appeal requests received on or after May 1, 2026, will be processed by C2C. CMS says there will be a short period where both Maximus and C2C will be issuing decisions. C2C began posting important updates on its website (https://www.c2cinc.com/) regarding the procedures for submitting appeals case files (such as secure portal registration and usage information, mailing address, etc.), as well as other communication protocols beginning on April 1, and will continue to do so throughout the transition.
Comments